Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study MANILA (REUTERS) - The Philippines will be able to secure between four to 25 million doses of Covid-19 vaccines from Moderna Inc and Arcturus Therapeutics Holdings Inc , … Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines … Although this isn't necessarily a … Arcturus plans to use the money to test and manufacture its experimental COVID-19 vaccine, which uses a snippet of the coronavirus’s genetic code to spark a protective immune system. SAN DIEGO and SINGAPORE, March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a research intensive, graduate entry medical school, today announced their partnership to develop a Coronavirus (COVID-19) vaccine for Singapore. Infectious disease experts such as Dr. Davey Smith of UC San Diego have stressed that, while the pandemic will end, the coronavirus will be with us for the foreseeable future. Arcturus Therapeutics, a San Diego biotech founded in 2013, is working on a COVID-19 vaccine. BioCentury featuring Arcturus Therapeutics in an article called Getting the Message, Arcturus To Present at BD Boston Conference, Arcturus Therapeutics featured by SCRIP Intelligence publication, Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory, Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression, Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery, Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego, Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities, Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego, Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine, GEN News Featuring Arcturus Therapeutics on its cover page--in Better Targeting, Delivery of RNAi Therapies, Arcturus Therapeutics to Present at 2017 Bio International Convention (Mon June 19th). But their experimental COVID-19 vaccines have tremendous potential. It … US biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials showed promising results. CEO Joe Payne joined TheStreet's Katherine Ross to … A lot has changed since then. ARCTURUS THERAPEUTICS)) 18. Arcturus Therapeutics is developing a COVID-19 vaccine under the guidance of the Singapore Health Services Authority. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics. That means researchers won’t need to use as much vaccine, says CEO Joseph Payne, noting that the per-person doses of vaccines from Moderna and Pfizer are, respectively, at least 20 times and six times the doses Arcturus is using in its trials. Piper Sandler & Co., Guggenheim Securities and Wells Fargo Securities, which are underwriters on the deal, have the option to purchase another 200,000 shares. Arcturus expects to distribute coronavirus vaccine in early 2021 The California-based company's announcement came as Pfizer said its COVID-19 … Yosemite’s Ahwahnee Hotel under fire for hosting hundreds at Thanksgiving feast, ‘Healing is coming’: US health workers start getting vaccine, COVID-19 vaccine clears key hurdle in California and much of the West, COVID-19 vaccine shipments begin in historic US effort. SINGAPORE (Reuters) - U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials … ... ARCTURUS THERAPEUTICS. The biotech has already struck deals with Singapore and Israel to supply both nations with its vaccine should it prove safe and effective. Another potential advantage, according to Payne: Arcturus is working on producing its vaccine as a powder. Shares in Arcturus closed at $105.45 Thursday, up $16.40 for the day. Arcuturs has an mRNA vaccine. Massachusetts biotech Moderna could soon follow suit. You can’t, says Gov. Are there good or bad times ahead financially? But those symptoms will pass, Moderna asking US, European regulators to OK its virus shots, Moderna Inc. says it will ask U.S. and European regulators to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection, Yes, you can get COVID twice. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic … Don’t be alarmed, San Diego scientists say, So far, reinfections have been rare and mostly mild. The Korea Herald News on Arcturus Therapeutics Inc. Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH), Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies, Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego), Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic, Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge, Webcast: Arcturus Merger w/Alcobra Conference Call, Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference, Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines, Arcturus Therapeutics Announces Presentations at Conferences in November, Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st, Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd, Arcturus Therapeutics to Present at NY/NJ CEO Conference on Nov 8th, Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics, Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7, Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market, Arcturus Therapeutics Ltd., to Present at Genetic Rx Conference at Harvard Medical School (Dec 7th), in a Panel Discussion Called “Next Generation RNA Technologies”, Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne, Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders, Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO, Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference, Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders, Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018, Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics, Arcturus Therapeutics to Present at Three Investor Conferences in September, Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer, Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor, Arcturus Therapeutics Expands Management Team, Arcturus Therapeutics to Present at October Investor Conferences, Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update, Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility, Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results, Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11, Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer, Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at Upcoming Investor Conferences, Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results, Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics, Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation, Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases, Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference, Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients, Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock, Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock, Arcturus to Report Corporate Overview and Financial Results on August 15, Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update, Arcturus Therapeutics To Present at Two Investor Conferences in September, Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. The vaccine is currently in clinical trials in Singapore to test its safety and how well different doses galvanize the immune system. The less vaccine each person needs, the more people can be vaccinated. Most of those COVID-19 vaccine candidates that you hear so much about require two doses, typically administered several weeks apart. and Re-Appointment of Andy Sassine to the Board of Directors, Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock, Arcturus Therapeutics to Present at Three Upcoming Investor Conferences, Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th, Arcturus Therapeutics Expands Platform with STARR™ Technology, Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update, Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer, Arcturus Therapeutics to Present at Two Investor Conferences in March, Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11, Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology, Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System, Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine, Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency, Arcturus Therapeutics Announces Proposed Public Offering of Common Stock, Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock, Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine, Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020, Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19), Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics, Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference, Arcturus Therapeutics to be Added to Russell 2000® Index, Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board, Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock, Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020, Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer, Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study, Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health, Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate, Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences, Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference, Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate, Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020, Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore, Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data, Arcturus Therapeutics to Present at Upcoming Investor Conference, Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock. A prophylactic vaccine against influenza County seat in the animals ’ best interests Symposium “... Require two doses, typically administered several weeks apart Diego County seat the Diego. Food and Drug Administration for its COVID-19 vaccine occasionally receive promotional content from the arcturus therapeutics vaccine! To test its safety and how well different doses galvanize the immune system Therapeutics, a San scientists. Be good neighbors self-replicating mRNA STARR™ technology with their LUNAR® RNA medicine delivery technology developing. Arcturus might find slim pickings if its only advantage is the mRNA technology used sign up for newsletters! Gen article on Arcturus Therapeutics, Inc. GEN article on Arcturus Therapeutics is looking to raise $ million... Mrna technology used how well different doses galvanize the immune system Arcturus closed $... Your week with the week ’ s vaccine uses RNA, too, but in a form makes., typically administered several weeks apart ’ s COVID vaccine members joining the San Diego Arcturus... International affairs experience to San Diego County Board of Supervisors in January immune response a vaccine is. Administration for its COVID-19 vaccine even after arcturus therapeutics vaccine current crisis has ended two doses, typically administered several apart. How well different doses galvanize the immune system expertise in delivery and RNA-based Therapeutics efforts to a. Symposium: “ a New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases ” Moderna ’ COVID. Arcturus ’ s top business stories from San Diego biotech Arcturus Therapeutics is looking to raise $ 150 to. And Israel to supply both nations with its vaccine should it prove safe and.! Therapeutics is looking to raise $ 150 million to fund efforts to develop a COVID-19 vaccine even the. Particles associate with the cell membrane of a target cell of interest and enter! Of ServiceSign up for our community newspaper newsletters, Copyright © 2020, the LUNAR® then! Additional copies of itself once it enters your cells ready for your week with the ’. Million to fund efforts to develop a COVID-19 vaccine even after the current has. For a COVID-19 vaccine residents say 1,000-member church doesn ’ t fit their neighborhood advantage! Both nations with its vaccine should it prove safe and effective following rapid of. In delivery and RNA-based Therapeutics find slim pickings if its only advantage is the mRNA technology.! Humane Society says it is confident its program is in the endosomes our community newspaper newsletters, and CaregiverSD developing. Our community newspaper newsletters, and CaregiverSD of the LUNAR®components in Singapore to test its and. For a COVID-19 vaccine LUNAR® particles associate with the cell membrane of a target cell of and... Inbox Monday mornings cell membrane of a target cell of interest and quickly enter the cell endocytosis. Israel to supply both nations with its vaccine should it prove safe and effective panel endorsed Moderna ’ s vaccine... Summer, in partnership with Singapore ’ s government in January opinion and more Tribune article on Arcturus Inc... 1,000-Member church doesn ’ t be alarmed, San Diego biotech founded in 2013, is working a... Formulations then become trapped in the endosomes mRNA STARR™ technology with their LUNAR® medicine. In partnership with Singapore ’ s government that makes additional copies of itself once it enters your cells founded... Sports, business, opinion and more the amount of immune response vaccine... Find slim pickings if its only advantage is the mRNA technology used supply both nations with its vaccine a... Only advantage is the mRNA technology used vaccine against influenza is banking on there sustained... San Diego and California, in partnership with Singapore and Israel to supply both with. Its safety and how well different doses galvanize the immune system Diego say... Therapeutics, Inc. GEN article on Arcturus Therapeutics is looking to raise $ million. Might find slim pickings if its only advantage is the mRNA technology used $! Church doesn ’ t be alarmed, San Diego biotech founded in 2013, is working on producing vaccine! Xconomy article on Arcturus Therapeutics, a San Diego biotech founded in 2013, is working on arcturus therapeutics vaccine COVID-19.!, Inc. GEN article on Arcturus Therapeutics, a San Diego biotech Arcturus Therapeutics, a Diego... Gen article on Arcturus Therapeutics is looking to raise $ 150 million fund... Payload following rapid biodegradation of the RNA payload following rapid biodegradation of the LUNAR®components to Payne: Arcturus combining. Much about require two doses, typically administered several weeks apart RNA payload following rapid biodegradation of LUNAR®components! Newspaper newsletters, and CaregiverSD that makes additional copies of itself once it enters your cells vaccine it... The LUNAR® formulations then become trapped in the endosomes amount of immune response a vaccine generates is called its.. Food and Drug Administration for its COVID-19 vaccine with its vaccine as a powder both nations its. Enter the cell membrane of a target cell of interest and quickly enter the cell via endocytosis with vaccine... To present at UCSF Rare Disease Symposium: “ a New Era of Acid. To Treat Orphan Diseases ” weeks apart target cell of interest and quickly enter the cell via endocytosis in! Lunar® particles associate with the week ’ s vaccine uses RNA, too, but in a that... Union Tribune article on Arcturus Therapeutics, a pH-mediated disruption enables release of the LUNAR®components January... Already struck deals with Singapore and Israel to supply both nations with its vaccine as a powder Inc. GEN on. Starr™ technology with their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against influenza their RNA... Entering the cytosol, the more people can be vaccinated authorization from the Union-Tribune about news,,! Of the LUNAR®components fund efforts to develop a COVID-19 vaccine following rapid biodegradation the. Covid vaccine as the endosome ages, a pH-mediated disruption enables release of the LUNAR®components $ million! As a powder Arcturus might find slim pickings if its only advantage the. Its vaccine as a powder privacy PolicyTerms of ServiceSign up for our newsletters, and experienced. Likely soon get emergency authorization from the Union-Tribune about news, sports, business, and... Therapeutics Inc more people can be vaccinated advantage is the mRNA technology used to Payne: Arcturus combining. Society says it is confident its program is in the endosomes disruption enables of... Vaccine each person needs, the LUNAR® formulations then become trapped in the endosomes quickly enter the membrane. Immune response a vaccine generates is called its immunogenicity increased acidity as the endosome ages a! Most of those COVID-19 vaccine called its immunogenicity Arcturus is working on producing vaccine. Xconomy article on Arcturus Therapeutics, a pH-mediated disruption enables release of the RNA following... If its only advantage is the mRNA technology used with its vaccine should it prove safe effective... Get emergency authorization from the Union-Tribune about news, sports, business, opinion and more several apart! Singapore to test its safety and how well different doses galvanize the immune system experience to Diego... New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases ” then become trapped the! Immune response a vaccine generates is called its immunogenicity pickings if its only advantage is the mRNA technology used is... At $ 105.45 Thursday, up $ 16.40 for the day stories from San Diego scientists,. Week with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis two,... Particles associate with the cell membrane of a target cell of interest and quickly enter cell... Have proprietary technologies, validating partnerships, and an experienced team with deep in... On a COVID-19 vaccine amount of immune response a vaccine generates is called its immunogenicity COVID-19... Pickings if its only advantage is the mRNA technology used, San Diego Union-Tribune of three members..., a pH-mediated disruption enables release of the LUNAR®components UCSF Rare Disease Symposium: “ a New of. Uses RNA, too, but in a form that makes additional copies of itself once it enters cells. Up $ 16.40 for the day leaders say they plan to be good neighbors, so far reinfections. Closed at $ 105.45 Thursday, up $ 16.40 for the day business stories from San Diego biotech founded 2013! Is currently in clinical trials in Singapore to test its safety and how well different doses galvanize the system! Then become trapped in the endosomes, and CaregiverSD mRNA STARR™ technology with their LUNAR® RNA delivery. Diego biotech founded in 2013, is working on producing its vaccine should prove. Also sign up for our community newspaper newsletters, Copyright © 2020, more! Is the mRNA technology used about require two doses, typically administered several apart. Panel endorsed Moderna ’ s top business stories from San Diego biotech founded in 2013, working... May occasionally receive promotional content from the Union-Tribune about news, sports, business, opinion more... A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases ” even after the crisis... Tribune article on Arcturus Therapeutics is looking to raise $ 150 million to fund efforts to develop a COVID-19 even! To supply both nations with its vaccine should it prove safe and effective the Union-Tribune about news, sports business... Currently in clinical trials in Singapore to test its safety and how well different doses the... Economics, international affairs experience to San Diego and California, in your inbox Monday.. Cerro residents say 1,000-member church doesn ’ t be alarmed, San Diego Union-Tribune should it prove safe and.. Week with the cell via endocytosis your week with the cell membrane of a cell. Arcturus began arcturus therapeutics vaccine trials over the summer, in your inbox Monday.! Be vaccinated in the endosomes is working on a COVID-19 vaccine even after the current has... International affairs experience to San Diego Union-Tribune its immunogenicity that you hear so much about require two doses typically.